Industry News (Joint Venture)

Water Soluble Analogs of Taxol (Paclitaxel) Commercialized

Published in Cancer Weekly, June 22nd, 1998

BTG announced that it has signed an exclusive commercialization agreement with Virginia Tech Intellectual Properties, Inc. (VTIP), Blacksburg, Virginia, under which BTG markets the rights to paclitaxel analogs.

Paclitaxel is approved for the treatment of ovarian, breast, and lung cancers and Kaposi's sarcoma (KS), and shows promise for the treatment of a variety of other cancers.

Due to the low water solubility of paclitaxel, researchers have attempted to create water soluble analogs of paclitaxel which retain their anti-cancer activity and are highly stable. Additionally, the development of paclitaxel-resistance in cancer patients undergoing...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-06-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry